Dronabinol
- Generic Name
- Dronabinol
- Brand Names
- Marinol, Sativex, Syndros
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 1972-08-3
- Unique Ingredient Identifier
- 7J8897W37S
- Background
Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...
- Indication
Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
- Associated Conditions
- Anorexia, Chemotherapy-Induced Nausea and Vomiting
- Associated Therapies
- -
Cannabinoid Modulation of Pain
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 6
- Registration Number
- NCT01595620
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Cannabis Effects on Driving-related Skills of Young Drivers
- Conditions
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 99
- Registration Number
- NCT01592409
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
The Effects of ∆-9-THC and Naloxone in Humans
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 6
- Registration Number
- NCT01591629
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT01562483
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain
- Conditions
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT01551511
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01380457
- Locations
- 🇺🇸
BASi, Baltimore, Maryland, United States
Abuse Potential of Sativex
- Conditions
- Interventions
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT01323569
- Locations
- 🇨🇦
DecisionLine Clinical Research Corporation, Toronto, Ontario, Canada
Study to Assess Food Effect on Sativex Bioavailability
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01322464
- Locations
- 🇬🇧
Guy's Drug Research Unit, Quintiles Ltd., London, United Kingdom
Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT01253408
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
The Effects of Cannabidiol and ∆-9-THC in Humans
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 27
- Registration Number
- NCT01180374
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.